Evercore ISI Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $205.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by Evercore ISI from $191.00 to $205.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday. TD Cowen cut their target price on Ascendis Pharma A/S from $175.00 to $157.00 and set a buy rating for the company in a research report on Wednesday, September 4th. Bank of America lifted their price target on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a buy rating in a research report on Wednesday, September 4th. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Up 3.1 %

ASND stock opened at $153.43 on Tuesday. The company has a 50-day simple moving average of $132.94 and a 200 day simple moving average of $136.52. The company has a market capitalization of $8.93 billion, a P/E ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ASND. Profund Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its position in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.